Step­ping out as a glob­al play­er, a re­struc­tured Take­da en­rolls 20,000-plus in new dengue PhI­II in a show­down with Sanofi

Christophe We­ber, pres­i­dent and chief ex­ec­u­tive of­fi­cer of Take­da Phar­ma­ceu­ti­cal Co., speaks dur­ing the 18th Nikkei Glob­al Man­age­ment Fo­rum in Tokyo, Japan  (CRED­IT: To­mo­hi­ro Ohsu­mi/Bloomberg via Get­ty Im­ages)

Last sum­mer, when Take­da set out to re­struc­ture its glob­al R&D op­er­a­tions, CEO Christophe We­ber ze­roed in on four key ar­eas: can­cer, GI, CNS dis­eases and vac­cines. Part of that com­mit­ment to vac­cines in­clud­ed a makeover in­to a glob­al play­er. And to­day the bio­phar­ma com­pa­ny took a big step for­ward in that di­rec­tion with the com­ple­tion of en­roll­ment of more than 20,000 kids in­to a piv­otal Phase III test of a new dengue vac­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER